Jaguar Gene Therapy nabs $139M to develop AAV9-based gene therapies

By The Science Advisory Board staff writers

Jaguar Gene Therapy has closed $139 million in funding to advance its preclinical pipeline of adeno-associated virus 9 (AAV9)-based gene therapies.

The company's pipeline includes three agents: JAG101, a gene therapy treatment in development for galactosemia; JAG201, a gene therapy treatment in development for a specific genetic cause of autism spectrum disorder; and JAG301, a gene therapy treatment in development for type 1 diabetes.

Jaguar's subsidiary, Axovia Therapeutics, is also advancing AXV101, a gene therapy treatment for subset of Bardet-Biedl syndrome (BBS), BBS1.

The series B funding was co-led by Eli Lilly and Deerfield Management. Additional investors include ARCH Venture Fund XI, the Goldman Sachs fund, and Nolan Capital.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?